ANGPTL8 and metabolic dysfunction-associated steatotic liver disease: However, given the chronic nature of NAFLD, longer term preclinical studies would be required to assess the effectiveness of Angptl8-ASO in this setting to understand its capacity to prevent subsequent conditions such as NASH.